Changeflow GovPing Healthcare & Life Sciences Ebola Monoclonal Antibody Cocktail Patent, Apri...
Routine Notice Added Final

Ebola Monoclonal Antibody Cocktail Patent, April 2026

Favicon for changeflow.com EPO Patent Bulletin - Pharma (A61K)
Published
Detected
Email

Summary

The EPO published patent application EP3583122A1 titled 'Monoclonal Antibodies and Cocktails for Treatment of Ebola Infections,' filed by Mapp Biopharmaceutical, Inc., Albert Einstein College of Medicine, and Adimab, LLC. Five named inventors are listed: Bornholdt, Zeitlin, Chandran, Wec, and Walker. The application covers designated states across all EU member states plus several additional European countries.

“MONOCLONAL ANTIBODIES AND COCKTAILS FOR TREATMENT OF EBOLA INFECTIONS”

EPO , verbatim from source
Published by EPO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors EPO Patent Bulletin - Pharma (A61K) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 58 changes logged to date.

What changed

The EPO Patent Bulletin published application EP3583122A1 for monoclonal antibodies and antibody cocktails intended for treating Ebola virus infections. The application names Mapp Biopharmaceutical, Inc., Albert Einstein College of Medicine, and Adimab, LLC as co-applicants, with five named inventors. The designated states include all EU member states plus Albania, Switzerland, Norway, Iceland, Liechtenstein, Monaco, North Macedonia, Serbia, San Marino, Turkey, and Vatican City.

Pharmaceutical and biotechnology companies engaged in infectious disease therapeutic development should note this filing as part of the competitive landscape for Ebola treatments. The publication provides public notice of the pending application and opens the period for third-party observations or opposition under EPO procedures.

Archived snapshot

Apr 24, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

MONOCLONAL ANTIBODIES AND COCKTAILS FOR TREATMENT OF EBOLA INFECTIONS

Publication EP3583122A1 Kind: A1 Apr 15, 2026

Applicants

Mapp Biopharmaceutical, Inc., Albert Einstein College of Medicine, Adimab, LLC

Inventors

BORNHOLDT, Zachary, A., ZEITLIN, Larry, CHANDRAN, Kartik, WEC, Anna, WALKER, Laura

IPC Classifications

C07K 16/10 20060101AFI20201008BHEP A61P 31/14 20060101ALI20201008BHEP A61K 39/395 20060101ALI20201008BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Pharma (A61K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 15th, 2026
Instrument
Notice
Branch
International
Legal weight
Non-binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Pharmaceutical companies Healthcare providers Medical device makers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Monoclonal antibody patents Therapeutic drug development Infectious disease treatments
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Regulatory Affairs
Topics
Pharmaceuticals Public Health

Get alerts for this source

We'll email you when EPO Patent Bulletin - Pharma (A61K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!